Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 369465, 7 pages
Clinical Study

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

1Institute of Neurology, IRCCS San Raffaele, Via della Pisana 235, 00163 Rome, Italy
2Vernalis (R&D) Ltd., Reading Road, Winnersh, Berkshire RG41 5UA, UK
3Chiesi Farmaceutici SpA, 43100 Parma, Italy

Received 12 March 2015; Revised 5 May 2015; Accepted 18 May 2015

Academic Editor: Jan O. Aasly

Copyright © 2015 Fabrizio Stocchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Table 1: Dosing schedule and post-dose blood draw times to obtain samples for pharmacokinetic analysis.

Supplementary Table 2: Demographic and baseline characteristics for all randomized patients.

Supplementary Table 3: Pharmacokinetic parameters for L-dopa: Cohort 1

Supplementary Table 4: Pharmacokinetic parameters for L-dopa: Cohort 2

  1. Supplementary Material